Full Press Release Details
SOUTH SAN FRANCISCO, Calif., March 25, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® therapeutic technology platform, today announced that on March 23, 2020, the Company granted its recently appointed senior vice president and chief financial officer, Carlos Campoy, an option to purchase a total of 350,000 shares of the Company’s common stock at an exercise price per share equal to $4.93, which was the closing trading price on March 23, 2020, the date of the grant.
The stock options were granted pursuant to the Company’s 2019 Employment Inducement Incentive Plan, which was approved by the Company’s board of directors in September 2019 under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.
About CytomX Therapeutics
PROBODY is a U.S. registered trademark of CytomX Therapeutics, Inc.
Investors and Media:
VP, Investor Relations and Corporate Communications